Risks and benefits associated with novel
β
Shlomo A. Koyfman; Manish Agrawal; Elizabeth Garrett-Mayer; Benjamin Krohmal; El
π
Article
π
2007
π
John Wiley and Sons
π
English
β 210 KB
## Abstract ## BACKGROUND. Although aggressive dose escalation strategies were designed to improve the riskβbenefit profile of phase 1 oncology trials, they have not been adequately studied. The prevalence of several novel trial designs and their association with a variety of clinical endpoints wa